Study guide
3.3 Obstetric DIC, Coagulopathy & Massive Transfusion Protocol (MTP)
C-OBE Obstetric Emergencies Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Maternal Assessment, Risk Stratification & Early Warning Systems
1.1 Pre-Existing Medical, Surgical & Obstetric Comorbidities in Emergency Risk Stratification 1.2 Dynamic Antepartum & Intrapartum Risk Assessment 1.3 Maternal Early Warning Systems (MEWS/MEWT) & Critical Triage Physical Assessment 1.4 Alliance for Innovation on Maternal Health (AIM) Safety Bundles & Emergency Readiness
2 Chapter 2: Obstetric Hemorrhage — Etiology, Assessment & Uterotonics
2.1 Postpartum Hemorrhage Etiology (4 T's) & Quantitative Blood Loss (QBL) 2.2 Uterotonic Pharmacology & Stepwise Administration Protocols 2.3 Tranexamic Acid (TXA) Protocols & Hemorrhage Timing
3 Chapter 3: Obstetric Hemorrhage — Mechanical Interventions, Placental Disorders & Transfusion
3.1 Intrauterine Tamponade Balloons, Compression Sutures & Surgical Hemostasis 3.2 Ectopic Pregnancy, Placenta Previa, Accreta Spectrum (PAS), Abruption & Vasa Previa 3.3 Obstetric DIC, Coagulopathy & Massive Transfusion Protocol (MTP)
4 Chapter 4: Hypertensive Disorders of Pregnancy & Preeclampsia with Severe Features
4.1 Classification & Spectrum of Hypertensive Disorders of Pregnancy 4.2 Preeclampsia with Severe Features: Pathophysiology & End-Organ Damage 4.3 Diagnostic Evaluation, Laboratory Triggers & Fetal Surveillance in Preeclampsia
5 Chapter 5: Hypertensive Crisis, Eclampsia & Magnesium Sulfate Therapy
5.1 Acute Severe Hypertension & First-Line Antihypertensive Protocols 5.2 Eclampsia Recognition, Seizure Management & Airway Protection 5.3 Magnesium Sulfate Neuroprotection/Seizure Prophylaxis Protocols, Monitoring & Toxicity Reversal 5.4 HELLP Syndrome & Hepatic Crisis Management
6 Chapter 6: Maternal Resuscitation, Cardiac Arrest & Perimortem Cesarean
6.1 Maternal ACLS Modifications & Cardiopulmonary Resuscitation Physiology 6.2 Etiologies of Maternal Arrest & Structured Emergency Response 6.3 Perimortem Cesarean Delivery (PMCD / Resuscitative Hysterotomy)
7 Chapter 7: Amniotic Fluid Embolism & Maternal Shock States
7.1 Amniotic Fluid Embolism (AFE): Pathophysiology & Clinical Presentation 7.2 A-OK Protocol, Hemodynamic Support & Critical Care in AFE 7.3 Maternal Shock States: Hemorrhagic, Distributive, Cardiogenic & Obstructive
8 Chapter 8: Acute Intrapartum Delivery Emergencies
8.1 Shoulder Dystocia: Recognition, Timing & Primary HELPERR Sequence 8.2 Advanced Shoulder Dystocia Maneuvers & Neonatal Brachial Plexus Injury Prevention 8.3 Umbilical Cord Prolapse Recognition & Emergent Decompression Protocols
9 Chapter 9: Uterine Inversion, Malpresentation & Obstetric Trauma
9.1 Acute Uterine Inversion: Recognition, Tocolysis & Manual/Surgical Reduction 9.2 Emergency Vaginal Breech Extraction & Head Entrapment Maneuvers 9.3 Maternal Trauma: Primary/Secondary Survey, Placental Abruption & Fetomaternal Hemorrhage
10 Chapter 10: Maternal Sepsis, Intraamniotic Infection & Severe Infections
10.1 Maternal Sepsis: Physiological Criteria, S.O.S. Score & omSOFA 10.2 The Maternal Sepsis Hour-1 Bundle & Fluid/Vasopressor Optimization 10.3 Intraamniotic Infection (Triple I / Chorioamnionitis) & Severe Endometritis 10.4 Severe Pyelonephritis, Maternal Pneumonia & Severe Peripartum Infections
11 Chapter 11: Endocrine, Cardiovascular, Respiratory & Neurologic Emergencies
11.1 Diabetic Ketoacidosis (DKA), Maternal Hypoglycemia & Endocrine Resuscitation in Pregnancy 11.2 Peripartum Cardiomyopathy (PPCM), Acute Heart Failure, Acute Coronary Syndromes & Maternal Arrhythmias 11.3 Status Asthmaticus, Pulmonary Edema & ARDS in Pregnancy 11.4 Status Epilepticus, Acute Stroke & Cerebral Venous Sinus Thrombosis (CVST)
12 Chapter 12: Thromboembolism, Hepatorenal Disorders & Toxicologic Emergencies
12.1 Venous Thromboembolism (DVT/PE) Diagnosis, Treatment & Peripartum Anticoagulation 12.2 Acute Fatty Liver of Pregnancy (AFLP / Swansea Criteria) & Acute Kidney Injury 12.3 Peripartum Substance Overdose, Opioid Toxicity & Naloxone Administration
13 Chapter 13: Obstetric Anesthesia Emergencies & Critical Complications
13.1 High Spinal / Total Spinal Anesthesia & Aspiration Pneumonitis 13.2 Local Anesthetic Systemic Toxicity (LAST) & 20% Lipid Emulsion Rescue Protocol 13.3 Post-Dural Puncture Headache (PDPH), Epidural Hematoma & Abscess 13.4 Malignant Hyperthermia in Obstetric Anesthesia & Dantrolene Protocol
14 Chapter 14: Professional Practice, Team Communication, Debriefing & Health Equity
14.1 Crisis Resource Management (CRM), TeamSTEPPS & Structured Communication 14.2 Multidisciplinary Emergency Debriefing, Morbidity & Mortality, and Systems Learning 14.3 Perinatal Racial/Ethnic Disparities, Implicit Bias Mitigation & Respectful Maternity Care 14.4 Legal, Ethical, Documentation & EMTALA Standards in Obstetric Emergencies
3.3 Obstetric DIC, Coagulopathy & Massive Transfusion Protocol (MTP)
Key Takeaways Explain This Topic AI
Normal pregnancy elevates baseline fibrinogen to 400–600 mg/dL; in an actively bleeding parturient, a fibrinogen level <200 mg/dL indicates severe consumptive coagulopathy and independently predicts life-threatening hemorrhage and massive transfusion requirements.
Obstetric Massive Transfusion Protocols (MTP) mandate balanced 1:1:1 reconstitution (Packed Red Blood Cells : Fresh Frozen Plasma : Platelets) to prevent iatrogenic dilutional coagulopathy and optimize microvascular hemostasis early in resuscitation.
Targeted cryoprecipitate administration (1 pool / 10 units raises plasma fibrinogen by 50–100 mg/dL) is the therapy of choice for hypofibrinogenemia (<200 mg/dL) to restore hemostasis without causing Transfusion-Associated Circulatory Overload (TACO).
Resuscitation must proactively prevent the 'lethal triad' (hypothermia, acidosis, coagulopathy) through aggressive fluid/patient warming, ionized calcium surveillance with empirical IV calcium repletion for citrated blood toxicity, and consideration of intraoperative cell salvage.
Last updated: August 2026
Obstetric DIC, Coagulopathy & Massive Transfusion Protocol (MTP)
Obstetric hemorrhage is uniquely hazardous because severe blood loss frequently coexists with or triggers acute consumptive coagulopathy and Disseminated Intravascular Coagulation (DIC) . Failure to recognize the distinct physiologic coagulation profile of pregnancy and delays in initiating balanced Massive Transfusion Protocols (MTP) are leading causes of maternal hemorrhage-related mortality.
1. Pregnancy Hemostasis & Pathophysiology of Obstetric DIC
Normal pregnancy is an adaptive hypercoagulable state characterized by marked increases in procoagulant factors (Fibrinogen, Factors VII, VIII, IX, X, XII, and von Willebrand factor), decreases in natural anticoagulants (Protein S), and profound suppression of fibrinolysis mediated by placental plasminogen activator inhibitors (PAI-1 and PAI-2). While this state limits blood loss during normal placental separation, it makes the parturient uniquely vulnerable to explosive consumptive coagulopathy when exposed to systemic procoagulants. +---------------------------------------------------------------------------------------+
- | THE PATHOPHYSIOLOGIC CASCADE OF OBSTETRIC DIC |
- | |
- | [ETIOLOGIC TRIGGERS] |
- | - Severe Placental Abruption (Decidual Tissue Factor release) |
- | - Amniotic Fluid Embolism / AFE (Procoagulant fetal antigens / tissue factor) |
- | - Septic Shock / Chorioamnionitis (Endotoxin / Cytokine-mediated activation) |
- | - Retained Dead Fetus (>4–6 weeks; necrotic tissue thromboplastin release) |
- | - Severe Preeclampsia / HELLP Syndrome (Diffuse endothelial injury) |
- | | |
- | v |
- | [MASSIVE SYSTEMIC THROMBIN GENERATION] |
- | - Uncontrolled conversion of prothrombin to thrombin throughout the vasculature |
- | | |
- | v |
- | [MICROVASCULAR THROMBOSIS & END-ORGAN ISCHEMIA] |
- | - Widespread fibrin deposition in microcirculation --> Renal / Hepatic / Lung Injury|
- | - Microangiopathic hemolytic anemia (schistocytes on smear) |
- | | |
- | v |
- | [RAPID CONSUMPTION OF COAGULATION FACTORS & PLATELETS] |
- | - Severe depletion of Fibrinogen, Platelets, Factor V, Factor VIII, Prothrombin |
- | | |
- | v |
- | [SECONDARY HYPERFIBRINOLYSIS] |
- | - Massive plasmin generation --> Fibrin Degradation Products (FDPs) & D-Dimers |
- | - FDPs actively inhibit platelet aggregation and impair myometrial contraction |
- | | |
- | v |
- | [CATASTROPHIC GENERALIZED HEMORRHAGE] |
- | - Spontaneous bleeding from IV sites, surgical incisions, urinary catheter, mucosa |
- +---------------------------------------------------------------------------------------+
Critical Difference in Pregnancy Coagulation Baselines:
In non-pregnant individuals, baseline fibrinogen is 200 to 400 mg/dL .
In the third trimester of pregnancy, baseline fibrinogen rises physiologically to 400 to 600 mg/dL .
The Critical Clinical Pitfall: A fibrinogen level of 200 mg/dL is technically within the 'normal range' for a non-pregnant patient, but in an acutely bleeding parturient, a fibrinogen of <200 mg/dL represents a critical, life-threatening depletion of 50% to 66% of her circulating fibrinogen , signaling severe consumptive coagulopathy and predicting the imminent need for massive transfusion.
2. Laboratory Markers & Point-of-Care Viscoelastic Hemostatic Testing
Rapid, accurate monitoring of coagulation status is vital during obstetric hemorrhage resuscitation. +---------------------------------------------------------------------------------------+
- | COAGULATION MONITORING IN OBSTETRICS |
- | |
- | +-----------------------------------+-------------------------------------------+ |
- | | STANDARD LABORATORY PANEL | VISCOELASTIC TESTING (TEG / ROTEM) | |
- | +-----------------------------------+-------------------------------------------+ |
- | | - Turnaround time: 45–60 minutes | - Turnaround time: 10–15 minutes (Bedside)| |
- | | - Static plasma factor levels | - Dynamic, whole-blood functional clot | |
- | | - Fibrinogen <200 mg/dL: Critical | formation, strength & fibrinolysis | |
- | | - Platelets <50k: Transfusion | - Rapidly differentiates hypofibrinogenemia| |
- | | - PT/INR >1.5: Factor deficiency | from platelet dysfunction | |
- | | - 'Red Top' Tube: Bedside check | - Guides targeted component replacement | |
- | +-----------------------------------+-------------------------------------------+ |
- +---------------------------------------------------------------------------------------+
The Bedside 'Red Top Tube' Clot Observation Test:
When laboratory results are delayed, the bedside Lee-White / Red Top Clot Test provides an immediate qualitative assessment of fibrinogen:
Draw 5 mL of maternal venous blood into a plain glass tube (no anticoagulant/additives, red-top tube).
Hold the tube upright or tape it to the wall at room temperature.
Normal: A solid, firm clot forms within 6 to 10 minutes and does not lyse when inverted.
Severe Hypofibrinogenemia (<150 mg/dL): No clot forms after 10–15 minutes, or a fragile, small clot forms that completely dissolves (lyses) within 30 minutes. This confirms severe consumptive coagulopathy.
Viscoelastic Point-of-Care Testing (TEG & ROTEM):
Thromboelastography (TEG) and Rotational Thromboelastometry (ROTEM) evaluate whole blood viscoelastic properties from initial fibrin formation through maximum clot strength and fibrinolysis:
Viscoelastic Parameter TEG Metric ROTEM Metric Physiologic Process Evaluated Targeted Clinical Intervention
Clotting Initiation R-time (Reaction time) CT (Clotting Time) Coagulation factor activity & thrombin generation Prolonged: Transfuse Fresh Frozen Plasma (FFP)
Clot Kinetics K-time / α \alpha α -angle CFT / α \alpha α -angle Speed of fibrin mesh build-up and crosslinking Prolonged K / Low angle: Give Cryoprecipitate / Fibrinogen
Maximum Clot Strength MA (Maximum Amplitude) MCF (Max Clot Firmness) Platelet count/function (80%) + Fibrinogen (20%) Low MA / MCF: Transfuse Platelets + Cryoprecipitate
Functional Fibrinogen FLEV / FF MA FIBTEM MCF Isolated fibrinogen contribution (platelets inhibited) FIBTEM <10–12 mm : STAT Cryoprecipitate (10 units)
Clot Lysis (Fibrinolysis) LY30 (Lysis at 30 min) ML / LY30 Degree of hyperfibrinolysis Elevated (>3%): STAT Tranexamic Acid (1 g IV)
3. Obstetric Massive Transfusion Protocol (MTP)
An Obstetric MTP is an institutional, emergency blood bank protocol designed to deliver pre-assembled, balanced blood components immediately to the bedside, eliminating the delays of crossmatching and order verification. +---------------------------------------------------------------------------------------+
- | OBSTETRIC MASSIVE TRANSFUSION PROTOCOL (1:1:1) |
- | |
- | [MTP ACTIVATION CRITERIA] |
- | - Cumulative QBL >1,500–2,000 mL with ongoing active bleeding |
- | - Persistent hemodynamic instability (HR >120, SBP <80, Shock Index >1.0) |
- | - Clinical evidence of coagulopathy (oozing from IV sites/incisions) |
- | - Transfusion of >4 units PRBCs within 1 hour with anticipated continued need |
- | | |
- | v |
- | [MTP COOLER 1 (IMMEDIATE RELEASE)] |
- | - 4 to 6 units O-Negative (or Type-Specific) PRBCs |
- | - 4 units AB (or A) Fresh Frozen Plasma (FFP) |
- | | |
- | v |
- | [MTP COOLER 2 (BALANCED 1:1:1 RESUSCITATION)] |
- | - 4 to 6 units PRBCs |
- | - 4 to 6 units FFP |
- | - 1 Apheresis Unit Platelets (equivalent to 6 pooled platelet units) |
- | - 10 units (1 pool) Cryoprecipitate (or Fibrinogen Concentrate) |
- | | |
- | v |
- | [CRITICAL METABOLIC & ADJUNCTIVE PROTOCOLS] |
- | - Tranexamic Acid (TXA): 1 g IV over 10 min within 3 hrs of onset |
- | - Calcium Gluconate: 1 g IV per every 4 units PRBCs (target iCa >1.1 mmol/L) |
- | - Active Warming: Rapid infusers, Bair Hugger (target core temp >36°C) |
- +---------------------------------------------------------------------------------------+
Blood Component Characteristics & Targets:
Blood Component Content & Unit Volume Impact per Unit Transfused Clinical Target in Obstetric MTP
Packed Red Blood Cells (PRBCs) RBCs, hematocrit ~60%, volume ~300 mL Increases Hemoglobin by ~1 g/dL (Hematocrit by ~3%) Hemoglobin >8 g/dL (Hct >24%)
Fresh Frozen Plasma (FFP) All coagulation factors, fibrinogen (~2 g/L), volume ~250 mL Replenishes depleted clotting factors; requires thawing (20–30 min) PT / INR <1.5 , aPTT <1.5x control
Platelets 1 Apheresis unit (or 6 pooled units), volume ~300 mL Increases platelet count by 30,000 to 50,000 / μ \mu μ L Platelets >50,000 / μ \mu μ L (>100k if ongoing surgical trauma)
Cryoprecipitate Cold-insoluble precipitate of FFP; 1 pool (10 units) has ~150–200 mL Rich in Fibrinogen (1.5–2.5 g/pool), Factor VIII, vWF, Factor XIII. 1 pool raises fibrinogen by 50–100 mg/dL Fibrinogen >150–200 mg/dL (Preferred over FFP for fibrinogen repletion)
Fibrinogen Concentrate Lyophilized, pathogen-reduced human fibrinogen (1–2 g vials) Rapid reconstitution in sterile water without thawing or crossmatch; raises fibrinogen precisely Fibrinogen >150–200 mg/dL (Dose: 2–4 g IV / 70 mg/kg)
Important
Why Cryoprecipitate is Superior to FFP for Hypofibrinogenemia: To raise a patient's plasma fibrinogen from 100 mg/dL to 200 mg/dL using FFP alone would require transfusing 8 to 12 units of FFP (2,000–3,000 mL of volume), risking severe Transfusion-Associated Circulatory Overload (TACO) and pulmonary edema. A single 10-unit pool of Cryoprecipitate delivers the same quantity of fibrinogen in only 150–200 mL of volume , restoring hemostasis rapidly without volume overload.
4. Preventing the 'Lethal Triad', Citrate Toxicity & Intraoperative Cell Salvage
Massive transfusion without rigorous metabolic control induces a self-reinforcing vicious cycle termed the Lethal Triad of Hemorrhage . +---------------------------------------------------------------------------------------+
- | THE LETHAL TRIAD |
- | |
- | [HYPOTHERMIA] |
- | (Temp <35.0°C) |
- | / \ |
- | / \ |
- | v v |
- | [COAGULOPATHY] <-----------> [METABOLIC ACIDOSIS] |
- | (Enzymes Impaired) (pH <7.20) |
- +---------------------------------------------------------------------------------------+
- 1. Hypothermia & Active Warming
Mechanism: Rapid infusion of cold blood products and room-temperature IV fluids lowers core maternal temperature. Each 1°C drop in temperature decreases clotting factor enzyme activity by 10% and severely impairs platelet activation.
Interventions: Maintain OR temperature at ≥ 24 \ge 24 ≥ 24 °C (75°F); warm all intravenous crystalloids and blood products through inline rapid infuser warming systems (e.g., Belmont, Level 1); apply upper and lower body forced-air warming blankets (Bair Hugger). Target core body temperature is >36.0°C .
2. Acidosis & Balanced Crystalloids
Mechanism: Tissue hypoperfusion produces lactic acidosis, and excessive infusion of 0.9% normal saline induces hyperchloremic metabolic acidosis. Severe acidemia (pH <7.20) reduces thrombin generation by more than 50% and accelerates fibrinolysis.
Interventions: Restore microvascular perfusion promptly; utilize balanced crystalloid solutions (Lactated Ringer's or Plasmalyte) rather than large volumes of 0.9% normal saline.
3. Citrate Toxicity & Ionized Calcium Management
Mechanism: Stored blood products (PRBCs and FFP) are preserved with sodium citrate, which binds and chelates free circulating ionized calcium ( C a 2 + Ca^{2+} C a 2 + ). Rapid transfusion overwhelms hepatic citrate clearance, causing severe acute hypocalcemia (ionized calcium <1.1 mmol/L).
Physiologic Impact: Calcium (Factor IV) is an obligatory cofactor for tenase and prothrombinase enzyme complexes, as well as cardiac excitation-contraction coupling. Severe hypocalcemia causes myocardial depression, prolonged QT interval, hypotension, and intractable microvascular coagulopathy.
Protocol: Monitor ionized calcium levels every 30 to 60 minutes. Empirically administer 1 g of IV Calcium Gluconate (or 1 g IV Calcium Chloride via central/dedicated line) for every 4 units of citrated blood products transfused , maintaining ionized calcium >1.1 to 1.2 mmol/L .
4. Intraoperative Cell Salvage (IOCS) in Obstetrics
Mechanism: Recovers shed surgical blood from the peritoneal cavity, washes and filters out debris, and re-infuses autologous concentrated packed red cells (hematocrit 50–60%).
Safety Profile: Historically withheld due to theoretical concerns of amniotic fluid embolism (AFE), modern consensus from ACOG, the American Society of Anesthesiologists (ASA), and the Society for Maternal-Fetal Medicine (SMFM) confirms that cell salvage with a leukodepletion filter (leukocyte reduction filter) is safe and effective in reducing allogeneic transfusion requirements.
Clinical Technique: Use a separate suction source for amniotic fluid until delivery of the infant, then switch to the cell saver suction for surgical blood loss. In Rh-negative patients delivering an Rh-positive infant, perform a Kleihauer-Betke test to calculate the required dose of Rh immune globulin (RhoGAM).